

PTO/SB/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL  
FORM**

(to be used for all correspondence after initial filing)

<b>Total Number of Pages in This Submission</b>	<b>Application Number</b>	10/689,438
	<b>Filing Date</b>	October 20, 2003
	<b>First Named Inventor</b>	Luk, et al.
	<b>Art Unit</b>	1624
	<b>Examiner Name</b>	
	<b>Attorney Docket Number</b>	21269 US2

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):
<b>Remarks</b> PTO 1449 and Post Card.		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

<b>Firm or Individual</b>	Patricia S. Rocha-Tramaloni
<b>Signature</b>	
<b>Date</b>	January 29, 2004

**CERTIFICATE OF TRANSMISSION/MAILING**

I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date January 29, 2004

<b>Typed or printed</b>	Patricia S. Rocha-Tramaloni		
<b>Signature</b>		<b>Date</b>	January 29, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s): Luk, et al.

Group: 1624

Serial No.: 10/689,438, filed October 20, 2003  
(Ref. No. 21269 US2)

For: **PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY**

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Nutley, New Jersey 07110  
Date: January 29, 2004

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.

Copies of documents A2-A6, B3, and C3-C21 listed on Form PTO-1449 are not enclosed as copies of these documents are already of record in copending U.S. Application Serial No. 10/623,972, filed July 21, 2003, Atty. Docket No. CD 21266 US1.

The Examiner's attention is specifically also directed to copending U.S. Application Serial No. 10/623,972, Atty. Docket No. CD 21266 US1.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/689,438  
Filed: October 20, 2003


Since the Supplemental Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,



Attorney for Applicant(s)  
Patricia S. Rocha-Tramaloni  
(Reg. No. 31,054)  
340 Kingsland Street  
Nutley, New Jersey 07110  
Telephone: (973) 235-2441  
Telefax: (973) 235-2363

138534



Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)				Application Number	10/689,438
				Filing Date	October 20, 2003
				First Name Inventor	Luk, et al.
				Group Art Unit	1624
Sheet 1 of 2				Attorney Docket Number	21269 US2

### U.S. PATENT DOCUMENTS


Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
	A2	2,949,466		Hoefle, et al.	08/16/1960
	A3	4,886,807		Kitamura, et al.	12/12/1989
	A4	3,939,084		Sullivan	02/17/1976
	A5	4,425,346		Horlington	01/10/1984
	A6	6,451,804		Dunn, et al.	09/17/2002

### FOREIGN PATENT DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>2</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
	B3	WO 02/18380 A1			F.Hoffmann-La Roche AG	03/07/2002	

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	C3	Ansel, H. et al., <i>Pharmaceutical Dosage Forms &amp; Drug Delivery Systems</i> 6 <sup>th</sup> Ed. 1995, pg. 196	
	C4	J. Alexander, et al., <i>J. Med. Chem.</i> 1988, Vol. 31, pgs. 318-322	
	C5	Masquelin et al., <i>Helvetica Chimica Acta</i> , Vol. 81 (1998) pgs. 646-659	
	C6	Devi, et al., <i>Indian Journal of Heterocyclic Chemistry</i> , Vol. 7, January – March, 1998, pgs. 193-196	
	C7	Tominaga et al., <i>Chemical &amp; Pharmaceutical Bulletin</i> , Vol. 32, No. 1, January 1984, pgs. 122-129	
	C8	Tominaga et al., <i>Heterocycles</i> , Vol. 12, No. 4. 1979, pgs. 503-504	
	C9	Marsh et al., <i>Chemical Communications</i> , 1996, pgs. 1527-1528	
	C10	<i>Z. Chem.</i> 20 Jg (1980) Heft. 11, pgs. 412-413	
	C11	Cappuccino et al., <i>Cancer Research</i> , Vol. 24, August 1964, pgs. 1243-1248	
	C12	Chatterjee et al., <i>J. Sci. Industr. Res.</i> , Vol. 17B, February, 1958, pgs. 63-70	
	C13	Chatterjee et al., <i>J. Sci. Industr. Res.</i> , Vol. 18B, July, 1959, pgs. 272-278	
	C14	Graboyes et al., <i>Pteridines X.</i> , Vol. 11 January 6, 1968, pgs. 568-573	
	C15	Grohe et al., <i>Liebigs Ann. Chem.</i> , 1974, pgs. 2066-2073	



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)				<b>Complete if Known</b>	
				Application Number	10/689,438
				Filing Date	October 20, 2003
				First Name Inventor	Luk, et al.
				Group Art Unit	1624
Sheet	2	of	2	Attorney Docket Number	21269 US2

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	C16	Gulevskaya et al., <i>Chemistry of Heterocyclic Compounds</i> , Vol. 30, No. 9, 1994, pgs. 1083-1091	
	C17	Hirota et al., <i>J. Chem. Soc. Perkin Trans. 1</i> , 1990, pgs. 123-128	
	C18	Srivastava, et al., <i>Combinatorial Chemistry &amp; High Throughout Screening</i> , 1999, 2, pgs. 33-37	
	C19	Taylor et al., <i>Pyrimido [4,5-D]Pyrimidines</i> , Vol. 82, pgs. 5711-5718	
	C20	Wamhoff et al., <i>Heterocycles</i> , Vol. 35, No. 2, 1993, pgs. 1055-1066	
	C21	M. Hirota et al., "A Facile Synthesis of 7-Substituted Pyrimido[4,5-d]-Pyrimidine-2,4-diones", <i>Synthesis</i> , pgs. 589-590 (1984)	
Examiner Signature			Date Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation or abstract is attached.

138535